Foralumab reduced microglial activity in people with nonactive SPMS, and this was linked to reductions in proinflammatory ...

Neffy nasal spray shows comparable efficacy to IM epinephrine for type I allergic reactions, with 92.3% symptom resolution after 1 dose.

Stanford's potential universal vaccine promises to shield against COVID, flu, and more. Could one spray change how we fight ...

Acute Respiratory Distress Syndrome (ARDS) remains a major cause of morbidity and mortality in critically ill patients worldwide, despite advances in ...

Researchers in Maryland are testing an experimental treatment designed to block common respiratory viruses – from colds, the ...

If proven effective in humans, this vaccine could potentially eliminate the need for separate annual jabs for illnesses like ...

Stanford Medicine researchers have developed an experimental nasal vaccine that shielded mouse lungs for at least three months against a striking range of respiratory threats, from SARS-CoV-2 and ...

A new study published in Science suggests a single nasal spray vaccine may protect against colds, flu, bacterial lung ...

Stanford Medicine researchers have developed an intranasal liposomal vaccine that protected mice against SARS-CoV-2, ...

A California jury has awarded $25 million to a man who claimed exposure to Pam cooking spray caused severe damage to his lungs. Roland Esparza of Los Angeles sued Conagra Brands, the maker of Pam, in ...

-Five poster presentations highlight clinical advancement of neffy, real-world usability and advantages of needle-free epinephrine delivery -Longer shelf life of nasal epinephrine compared with ...